Equinox Capital III, L.P. Completes the Recapitalization of Comprehensive NeuroScience, Inc.

WHITE PLAINS, NY – (November 18, 2004) Equinox Capital III, L.P. today announced that it has completed the recapitalization of Comprehensive NeuroScience, Inc. (“CNS”).

Founded in 1999, CNS is an integrated clinical research and knowledge development company specializing in neuropsychiatric and related disorders and has the largest network of clinical research sites for central nervous system trials in the nation.  Through its Drug Development and Clinical Trials divisions, CNS designs, implements and analyzes clinical development programs on behalf of pharmaceutical and biotechnology companies and contract research organizations.  CNS implements these trials within its 18 owned and operated clinical trial sites across the U.S.  The Company's Knowledge Transfer division provides data and analyses to pharmaceutical companies and health systems to make approved therapies widely available and improve physician use.  Through its three divisions, CNS is increasingly working with its pharmaceutical customers from early clinical development to market development of their drug therapies, allowing them to accelerate the availability and increase the appropriate use of marketable drug therapies.  For more information on CNS, please visit the corporate website at www.cnsclinicaltrials.com.

Equinox Capital, Inc., a private investment firm, is a leading provider of equity for lower middle-market corporate acquisitions, recapitalizations and growth capital financings.  Equinox manages approximately $75 million in committed capital and is licensed as a Small Business Investment Company by the United States Small Business Administration.  For further information, please contact Steven C. Rodger at 203-622-1605 x12, or visit the corporate website at www.equinox-capital.com.
    
Source: Equinox Capital, Inc.